How I Identify and Treat MF Patients With Ruxolitinib Failure
Description
Upon viewing this session, you will be able to:
• Define ruxolitinib failure
• Identify appropriate patients with myelofibrosis in need of second line or JAK inhibitor combination therapy
• Recognize patients receiving ruxolitinib that should proceed to hematopoietic stem cell transplantation
• Summarize investigational approaches for patients who fail ruxolitinib therapy
• Define ruxolitinib failure
• Identify appropriate patients with myelofibrosis in need of second line or JAK inhibitor combination therapy
• Recognize patients receiving ruxolitinib that should proceed to hematopoietic stem cell transplantation
• Summarize investigational approaches for patients who fail ruxolitinib therapy
Presenters
- John Mascarenhas, MD, Mount Sinai School of Medicine
Pricing
| Member Type | Price |
|---|---|
| List Price | $30.00 |
| Active, International, Emeritus, and Honorary Members | $20.00 |
| Associate, International Associate, Student, and Resident Members | $20.00 |
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2021 by American Society of Hematology